Drug
Mp0317 Gemcitabine Cisplatine Durvalumab
Mp0317 Gemcitabine Cisplatine Durvalumab: highest development phase Phase 2, developed by Molecular Partners. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Molecular Partners
Trials
| Drug | Phase | Indication |
|---|---|---|
| MP0317 + Gemcitabine + Cisplatine + Durvalumab NCT07036380 | Phase 2 | Advanced Biliary Tract Carcinoma |
Latest
No recent events.
Follow Mp0317 Gemcitabine Cisplatine Durvalumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.